Last updated: May 23, 2026
Milrinone lactate supply is concentrated in a small set of global API manufacturers and sterile-injectable contract manufacturers. Commercial availability depends on whether the buyer needs (1) milrinone lactate API, (2) milrinone base plus conversion to lactate salt, or (3) finished milrinone lactate injection (typically 20 mg/20 mL in a sterile vial format).
Which companies supply milrinone lactate API (active ingredient)?
Featured snippet answer: Milrinone lactate API suppliers are typically found among specialty generics and API producers rather than large scale commodity plants. Supply is commonly offered by firms that also manufacture cardiovascular injectables or purine-derivative intermediates.
Common supplier categories buyers encounter
- API producers supplying milrinone (free base) or milrinone lactate as salt.
- Intermediates manufacturers supplying regulated penultimate steps and requiring customer-specific salt formation.
- Contract API crystallization/salt-form units converting milrinone base to the lactate salt to meet particle size, polymorph, and assay targets.
What buyers should verify in qualification packages
- Salt form confirmation for lactate (as opposed to base).
- Residual solvents, elemental impurities, and polymorph/crystal form.
- Sterility relevance only if purchasing formulated sterile product (API does not need sterility).
Who supplies milrinone lactate injection (finished dosage form)?
Featured snippet answer: Finished milrinone lactate injection is supplied by injectable-focused generic manufacturers and branded generics that maintain sterile manufacturing capacity and controlled substance/controlled logistics SOPs for hospital distribution.
Injection-specific qualification checks
- Needle hub compatibility and vial closure integrity (if vial is used).
- Container closure system validation.
- Sterility assurance level, endotoxin limits, and hold time data.
- Labeling alignment with intended market (US, EU, UK, GCC, LATAM).
What suppliers provide milrinone lactate in the US market (NDC distribution)?
Featured snippet answer: In the US, milrinone lactate injection distribution is driven by FDA-approved manufacturers listed on the drug labeling and dispensing supply chains, typically via wholesalers and GPO contracts. Availability can be episodic when sterile fill-finish capacity tightens.
What determines US sourcing continuity
- Sterile fill-finish capacity utilization.
- Inspection outcomes for aseptic processing.
- Demand spikes driven by hospital formularies and ICU use patterns.
- Raw material lead times for lactate salt formation.
How does milrinone lactate salt supply chain differ from milrinone base sourcing?
Featured snippet answer: The milrinone molecule can be sourced as base, but the lactate salt step is a distinct supply risk because it requires crystallization control and validated salt-form specifications.
Where delays typically occur
- Lactate salt crystallization reproducibility (batch-to-batch).
- In-process hold times and filtration yield.
- Salt-form conversion testing (DSC/XRD/IR method suitability).
- Stability of salt form under shipping conditions.
Which suppliers also make related cardiotonic phosphodiesterase III intermediates?
Featured snippet answer: Many API suppliers that can make milrinone also have upstream purine-derivative intermediate capability, but not all offer the final lactate salt.
Upstream dependencies to map
- Key intermediate availability for the purine core and functional side-chain.
- Scalable hydrogenation/oxidation steps depending on the manufacturing route used.
- Qualified catalysts and solvent supply for commercial scale.
Are there contract manufacturing organizations (CMOs) for milrinone lactate injection?
Featured snippet answer: Milrinone lactate injection CMOs generally provide sterile fill-finish and packaging for injectable generics rather than holding all IP for API synthesis.
CMO scope that affects procurement timing
- Aseptic manufacturing slot lead time.
- Vial filling and stoppering technology fit.
- Extractables/leachables package compatibility with target vial/stopper components.
- Packaging line availability for NDC label builds.
How many global suppliers can typically qualify for milrinone lactate sourcing?
Featured snippet answer: Qualification is usually limited by (1) the specific salt form, (2) sterile injectable capability if finished product is required, and (3) inspection status in the target region.
Supplier count reality for purchasers
- API-only qualification often yields a broader shortlist.
- Finished sterile injectables typically yields a narrower, inspection-dependent shortlist.
What is the best procurement strategy for milrinone lactate supply risk?
Featured snippet answer: Buyers usually dual-source either (a) finished product from two sterile manufacturers or (b) API from two vendors plus a second salt-form/crystallization partner.
Typical risk controls
- Vendor qualification with at least two validated sources.
- Contract clauses for allocation during shortages.
- Incoming testing strategy for salt form, assay, and impurity profile.
- Safety stock tied to lead times and sterile release cycle.
Key Takeaways
- Milrinone lactate supply splits into API producers and sterile injectable finished-product manufacturers/CMOs.
- The lactate salt formation step can be a material sourcing and QA risk even if milrinone base is available.
- US availability is sensitive to sterile manufacturing capacity and inspection outcomes, so procurement planning often requires dual sourcing.
- Best practice for continuity is two qualified supply routes for either API and salt formation or finished sterile injection.
FAQs
- Who manufactures milrinone lactate injection for hospital distribution?
- Is milrinone lactate supplied more often as API or as finished sterile product?
- What documentation is required to qualify milrinone lactate salt form for pharma buyers?
- How can companies dual-source milrinone lactate during sterile fill-finish constraints?
- What common impurity and residual solvent tests apply to milrinone lactate API purchasing?
References
- FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (milrinone lactate injection listings).
- FDA Drug Shortages database (milrinone lactate or comparable injectable presentations, if listed).
- European Medicines Agency (EMA) product information for milrinone lactate-containing medicines (if applicable).
